Bolt Biotherapeutics Inc (FRA:6LP)
€ 0.692 -0.006 (-0.86%) Market Cap: 26.39 Mil Enterprise Value: -39.58 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 43/100

Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 07:35PM GMT
Release Date Price: €0.968 (-5.10%)
Maxwell Skor
Morgan Stanley & Co. LLC - Analyst

Great. Thank you for joining us. I'm Maxwell Skor, biotech analyst with Morgan Stanley and before we get started, I need to read an important disclosure. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures.

Great. Now, I'd like to welcome Randy Schatzman, CEO of Bolt Biotherapeutics. For those of us who are either new or revisiting the Bolt story, I think it would be great if we can talk about a high-level discussion of the platform followed by the lead asset, BDC-1001, and then future directions.

Randy Schatzman
Bolt Biotherapeutics - CEO

Yeah. I'd be happy to do that. Thanks for having us, Max. Good to be with you today.

Questions & Answers

Maxwell Skor
Morgan Stanley & Co. LLC - Analyst

Thank you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot